A new study could change the lives of millions of people living with inflammatory bowel diseases (IBD) who don’t respond to the current standard of care.
Researchers at the Kennedy Institute of Rheumatology and Translational Gastroenterology Unit, University of Oxford have identified a potential therapeutic target for IBD. The findings are of particular importance to the 40% of patients who don’t respond to anti-TNF therapy, the current treatment option available.